Comment on: Proposal for a new diagnostic classification of photodistributed Stevens–Johnson syndrome and toxic epidermal necrolysis, European Journal of Medical Research

Stevens–Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap (SJS/TEN), collectively referred to SJS/TEN, form a spectrum of severe life-threatening adverse drug reactions whose pathomechanism is not fully understood. The article "Photodistributed Stevens–Johnson Syndrome and Toxic Epidermal Necrolysis: A Systematic Review and Proposal for a New Diagnostic Classification" by McKinley et. al., discusses a distinct distribution of epidermal necrosis in SJS/TEN, attributable to preceding exposure to ultraviolet radiation (UVR), and relative sparing of photo-protected areas. After reviewing numerous cases within the Immune-mediated Adverse drug Reactions in African HIV endemic setting Register and Biorepository (IMARI-SA) at the University of Cape Town with a similar clinical pattern as those published by McKinley et. al., we propose that the relative sparing of some areas giving an impression of photo-distribution is due to localised increase in skin pressure that reduces the blood supply in that area below a critical threshold. A dip in blood supply below this critical threshold quantitively limited T lymphocytes and cytokines that drive SJS/TEN to reach and damage the skin.

Comment on: Proposal for a new diagnostic classification of

Poster Presentations - 2018 - Australasian Journal of Dermatology

Stevens–Johnson Syndrome and Toxic Epidermal Necrolysis

Medicina, Free Full-Text

Biologic treatment in pediatric Stevens-Johnson syndrome/toxic

Epidermal Necrolysis (Stevens–Johnson Syndrome and Toxic Epidermal

Clinical features, outcomes and treatment in children with drug

Stevens–Johnson syndrome and toxic epidermal necrolysis in a

Calaméo - Atlas Of Graft Versus Host Disease Approaches To

A bioinformatic approach to identify pathogenic variants for

Photodistributed Stevens–Johnson syndrome and toxic epidermal

Abstracts from the 8th Drug Hypersensitivity Meeting (DHM) - 2018